---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Scoliosis management and spinal surgery"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Scoliosis management and spinal surgery. Topics: Consensus guideline: surveillance and referral thresholds, Consensus guideline: scoliosis management across the lifespan, Natural History Study: frequency of surgery and recommendations for bracing and surgery, Spinal fusion and survival in severe scoliosis, and 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/scoliosis-management-and-spinal-surgery"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Scoliosis management and spinal surgery

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Scoliosis Management and Spinal Surgery

<a id="topic-2.2.2.1.4-1"></a>

### Consensus guideline: surveillance and referral thresholds

> “Increased risk of neuromuscular scoliosis after age 6; risk typically abates after puberty. This can progress rapidly if present, necessitating reobservation every 6 months if present. Supine X-ray and orthopaedic referral when scoliotic curvature greater than 20°; correction may be indicated when greater than 40°.”
> “Surveillance for scoliosis becomes an important preventive measure; some children (~20%) ultimately require spinal surgery for this comorbidity.”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.4-2"></a>

### Consensus guideline: scoliosis management across the lifespan

> “The second draft comprised 88 items with agreement to strong agreement achieved on 85, to form the final guideline document.”
> “A comprehensive, life-span approach to the management of scoliosis in Rett syndrome is recommended that takes into account factors such as physical activity, posture, nutritional and bone health needs.”
> “Surgery should be considered when the Cobb angle is approximately 40 degrees to 50 degrees and must be supported by specialist management of anesthesia, pain control, seizures, and early mobilization.”

Source: [Downs et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19644320/)

<a id="topic-2.2.2.1.4-3"></a>

### Natural History Study: frequency of surgery and recommendations for bracing and surgery

> “913 females with classic RTT were included.”
> “168 (18%) had surgical correction.”
> “In terms of the actual age distribution for the 168 participants who had surgical correction, the majority (86%) occurred between age 9 and 15, the median age was 12 years (min=5, max=21).”
> “As such, when curves reach 25°, we recommend implementation of bracing in hopes of retarding or minimizing further progression. However, once the curve reaches 40° or more, we strongly promote surgical intervention.”

Source: [Killian et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5461984/)

<a id="topic-2.2.2.1.4-4"></a>

### Spinal fusion and survival in severe scoliosis

> “After adjusting for mutation type and age of scoliosis onset, the rate of death was lower in the surgery group (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.12-0.74; p=0.009) compared to those without surgery.”
> “With appropriate cautions, spinal fusion confers an advantage to life expectancy in Rett syndrome.”

Source: [Downs et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26661519/)

<a id="topic-2.2.2.1.4-5"></a>

### US national trends and perioperative outcomes of posterior spinal fusion

> “Among 220 patients with RAS, 216 (98.2%) were females (mean age at surgery: 12.3±3.3 yr).”
> “RTT diagnosis independently predicted higher odds of any complications (odds ratio: 1.98, P < 0.001) and increased length of stay (odds ratio: 1.18, P = 0.009) for admissions for PSF.”
> “Surgical treatment for RAS is rare but increased over a 19-year period.”

Source: [Stone et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37642479/)

<a id="topic-2.2.2.1.4-6"></a>

### Growth-friendly surgery and posterior spinal fusion in early onset scoliosis

> “The study included 15 females with Rett syndrome. Five patients had MCGR and 10 underwent PSF.”
> “There was one complication per group.”
> “Both MCGR and PSF effectively control scoliosis in RS patients. PSF provides superior coronal curve correction, while MCGR promotes spinal growth.”

Source: [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40820925/)

<a id="topic-2.2.2.1.4-7"></a>

### Orthotics and timing of spinal fusion

> “Scoliosis in individuals with Rett syndrome often does not respond to orthotics.”
> “Surgeons usually try to wait until the child is at least 10 years of age before performing spinal fusion. They may often recommend bracing, physiotherapy and physical activity to delay surgery in order to allow for as much growth as possible.”

Source: [Maheshwari (2018)](https://www.ai-online.info/images/ai-ausgabe/2018/04-2018/orphan-supplement-6-2018/2018_4_S117-S124_Rett%20syndrome.pdf)

<a id="topic-2.2.2.1.4-8"></a>

### Multidisciplinary clinic cohort and systematic review: rates of scoliosis surgery

> “Scoliosis was diagnosed in 61 girls (59.2%) with 12 (11.7%) requiring spinal surgery at a median age of 12.5 years (IQR 12–15 years).”

Source: [Vilvarajan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454341/)

> “Nine studies reported surgical procedures, with 1.2%–50.0% of patients requiring scoliosis surgery.”

Source: [Rashid et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396111/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
